Teva Pharmaceutical Industries (TEVA) concentration risks

The company's disclosed concentration profile is anchored in a single high-share product-type exposure: total revenues from sales of generic medicines across all business segments were $9,421 million, or 55% of total revenues in the most recently reported period. This is a high-share, structural concentration reflecting the company's identity as one of the world's largest generic pharmaceutical manufacturers. The structural character is important context: unlike a customer dependency, the reliance on generic medicines reflects a deliberate strategic positioning across a broad portfolio of molecules and therapeutic categories rather than dependence on a single product or buyer. That said, the generic medicines business carries its own inherent pressures that are structural to the category: generic drug pricing in the United States has faced sustained competitive erosion as approvals accumulate, channel consolidation among pharmacy benefit managers and wholesalers increases buyer leverage, and first-to-file exclusivity periods are finite. With more than half of revenues tied to this dynamic, any acceleration in generic price deflation or a significant shift in payer formulary policies could have a disproportionate effect on consolidated revenues and margins. No customer, geographic, or supplier concentrations are disclosed beyond this segment-level exposure. The profile is therefore relatively simple: a high share of revenue is tied to a broad but structurally pressured product category, and the key monitoring dimension is the pricing environment for generic pharmaceuticals across the company's major markets.

For the engine’s reasoning on TEVA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.